Ga-68-PSMA-11 in Men With Prostate Cancer

• Status: Terminated
• Trial end date: 2022-04-14
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer. All patients will receive conventional imaging (MRI, CT, and/or a molecular imaging bone scan) as well as Ga-68-PSMA-11 PET in order to evaluate the utility of diagnostic testing in patients with positive PSA status, a comparison of results from conventional imaging and PSMA PET imagining will be performed.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Timothy Hoffman
• Collaborators: Harry S. Truman Memorial Veterans' Hospital; Telix Pharmaceuticals, Ltd; University of Missouri-Columbia
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• Able to tolerate PET/CT imaging and one or more of the following:

• Patients with newly diagnosed prostate cancer with primary staging classified at high/intermediate risk per NCCN guidelines OR

• Biochemical Recurrence: Patients with rising PSA after definitive therapy with prostatectomy or radiation therapy or other local therapies

Exclusion Criteria:

• Claustrophobia or any other condition that would preclude PET/CT imaging.

• Any constellation of medical conditions that indicate expectancy of less than one year